Shire (NASDAQ:SHPG) has been given a $186.00 target price by research analysts at Royal Bank of Canada in a research report issued to clients and investors on Sunday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would suggest a potential upside of 15.25% from the stock’s current price.
SHPG has been the topic of several other research reports. Cowen set a $225.00 price target on Shire and gave the company a “buy” rating in a research report on Friday, January 5th. JPMorgan Chase cut Shire from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $200.00 to $150.00 in a research report on Monday, February 19th. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a research report on Friday, March 23rd. Piper Jaffray restated a “hold” rating on shares of Shire in a research report on Wednesday, January 3rd. Finally, B. Riley boosted their price target on Shire to $200.00 and gave the company a “buy” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. Shire presently has a consensus rating of “Buy” and a consensus price target of $205.00.
Shire stock opened at $161.39 on Friday. Shire has a fifty-two week low of $123.73 and a fifty-two week high of $192.15. The company has a quick ratio of 0.55, a current ratio of 0.97 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $49,961.08, a PE ratio of 10.61, a PEG ratio of 1.23 and a beta of 1.30.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SHPG. SeaCrest Wealth Management LLC acquired a new position in Shire during the 4th quarter worth approximately $107,000. Avestar Capital LLC acquired a new position in Shire during the 4th quarter worth approximately $116,000. Amica Retiree Medical Trust acquired a new position in Shire during the 4th quarter worth approximately $120,000. Benjamin F. Edwards & Company Inc. increased its position in Shire by 277.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,253 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 921 shares during the period. Finally, Sawtooth Solutions LLC acquired a new position in Shire during the 4th quarter worth approximately $200,000. Institutional investors own 19.49% of the company’s stock.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.